Call it luck or design. But in the gallery of large Indian drug makers, Desh Bandhu Gupta is among the last men still holding their heads high. A tumultuous year has taken a toll on most domestic names. Companies had either bitten off more than they could chew by making expensive acquisitions or were caught on the wrong foot by the US federal inspectors picking holes in their quality control.
That limited start also set the tone of Gupta’s strategy in the US. As the distributor wanted only more of cephalosporin antibiotics, Lupin refrained from launching a large basket of products (unlike Ranbaxy and Dr. Reddys). As there was no great need to churn out copycat drugs, Lupin was doing new drug research with no immediate commercial benefit. For Lupin, therefore, US contributes to just 30 percent of its sales, lower than the 40-55 percent for competitors.
(This story appears in the 04 December, 2009 issue of Forbes India. To visit our Archives, click here.)
Dear Mr Desbandhu guptaji, How much share you feel drawing in promoting Aryuvedic medicines in your produccts, Can you focus- light on it.pls. thanks
on Jan 27, 2010